Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Details

Language :

English

ISSN :

00034967

Volume :

83

Issue :

8

Database :

Complementary Index

Journal :

Annals of the Rheumatic Diseases

Publication Type :

Academic Journal

Accession number :

179416882

Full Text :

https://doi.org/10.1136/ard-2023-225445